Hypoalbuminemia as Surrogate and Culprit of Infections

Abstract

Hypoalbuminemia is associated with the acquisition and severity of infectious diseases, and intact innate and adaptive immune responses depend on albumin. Albumin oxidation and breakdown affect interactions with bioactive lipid mediators that play important roles in antimicrobial defense and repair. There is bio-mechanistic plausibility for a causal link between hypoalbuminemia and increased risks of primary and secondary infections. Serum albumin levels have prognostic value for complications in viral, bacterial and fungal infections, and for infectious complications of non-infective chronic conditions. Hypoalbuminemia predicts the development of healthcare-associated infections, particularly with Clostridium difficile. In coronavirus disease 2019, hypoalbuminemia correlates with viral load and degree of acute lung injury and organ dysfunction. Non-oncotic properties of albumin affect the pharmacokinetics and pharmacodynamics of antimicrobials. Low serum albumin is associated with inadequate antimicrobial treatment. Infusion of human albumin solution (HAS) supplements endogenous albumin in patients with cirrhosis of the liver and effectively supported antimicrobial therapy in randomized controlled trials (RCTs). Evidence of the beneficial effects of HAS on infections in hypoalbuminemic patients without cirrhosis is largely observational. Prospective RCTs are underway and, if hypotheses are confirmed, could lead to changes in clinical practice for the management of hypoalbuminemic patients with infections or at risk of infectious complications.

References 216

1. 1.

   Ferrer R., Mateu X., Maseda E., Yébenes J.C., Aldecoa C., De Haro C., Ruiz-Rodriguez J.C., Garnacho-Montero J., Rodríguez J.C. Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients. Expert Rev. Clin. Pharmacol. 2018;11:125-137.

   Not in our library10.1080/17512433.2018.1412827

2. 2.

   Hariri G., Joffre J., DeRyckere S., Bigé N., Dumas G., Baudel J.-L., Maury E., Guidet B., Ait-Oufella H. Albumin infusion improves endothelial function in septic shock patients: A pilot study. Intensiv. Care Med. 2018;44:669-671.

   Not in our library10.1007/s00134-018-5075-2

3. 3.

   Bihari S., Bannard-Smith J., Bellomo R. Albumin as a drug: Its biological effects beyond volume expansion. Crit. Care Resusc. 2020;22:257-265.

   Not in our library10.1016/s1441-2772(23)00394-0

4. 4.

   Soeters P.B., Wolfe R.R., Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical Significance. J. Parenter. Enter. Nutr. 2019;43:181-193.

   Not in our library10.1002/jpen.1451

5. 5.
   Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units · 2010

   No notice
6. 6.

   Farcas A., Balcescu T., Anghel L., Bucsa C., Mogoșan C. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012. Expert Opin. Drug Saf. 2020;19:755-762.

   Not in our library10.1080/14740338.2020.1744561

7. 7.

   Melia D., Post B. Human albumin solutions in intensive care: A review. J. Intensiv. Care Soc. 2020;1751143720961245.

   Not in our library10.1177/1751143720961245

8. 8.

   Bernardi M., Angeli P., Claria J., Moreau R., Gines P., Jalan R., Caraceni P., Fernandez J., Gerbes A.L., O’Brien A.J., et al. Albumin in decompensated cirrhosis: New concepts and perspectives. Gut. 2020;69:1127-1138.

   Not in our library10.1136/gutjnl-2019-318843

9. 9.

   Angeli P., Bernardi M., Villanueva C., Francoz C., Mookerjee R.P., Trebicka J., Krag A., Laleman W., Gines P. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 2018;69:406-460.

   Not in our library10.1016/j.jhep.2018.03.024

10. 10.

    Zaccherini G., Tufoni M., Bernardi M. Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature. Hepatic Med. Évid. Res. 2020;12:153-172.

    Not in our library10.2147/hmer.s264231

11. 11.

    Fernández J., Angeli P., Trebicka J., Merli M., Gustot T., Alessandria C., Aagaard N.K., de Gottardi A., Welzel T.M., Gerbes A., et al. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. Clin. Gastroenterol. Hepatol. 2020;18:963-973.e14.

    Not in our library10.1016/j.cgh.2019.07.055

12. 12.

    China L., Maini A., Skene S.S., Shabir Z., Sylvestre Y., Colas R.A., Ly L., Salles N.B., Belloti V., Dalli J., et al. Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients with Advanced Liver Disease. Clin. Gastroenterol. Hepatol. 2018;16:738-747.e7.

    Not in our library10.1016/j.cgh.2017.08.027

13. 13.

    China L., Skene S.S., Bennett K., Shabir Z., Hamilton R., Bevan S., Chandler T., Maini A.A., Becares N., Gilroy D., et al. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: Study protocol for an interventional randomised controlled trial. BMJ Open. 2018;8:e023754.

    Not in our library10.1136/bmjopen-2018-023754

14. 14.

    Roche M., Rondeau P., Singh N.R., Tarnus E., Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582:1783-1787.

    Not in our library10.1016/j.febslet.2008.04.057

15. 15.

    Levitt D.G., Levitt M.D. Human serum albumin homeostasis: A new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int. J. Gen. Med. 2016;9:229-255.

    Not in our library10.2147/ijgm.s102819

16. 16.

    Gradel K.O., Vinholt P.J., Magnussen B., Pedersen C., Jensen T.G., Kolmos H.J., Lassen A.T. Hypoalbuminaemia as a marker of trans-capillary leakage in community-acquired bacteraemia patients. Epidemiol. Infect. 2018;146:648-655.

    Not in our library10.1017/s0950268818000274

17. 17.

    Iwao Y., Anraku M., Yamasaki K., Kragh-Hansen U., Kawai K., Maruyama T., Otagiri M. Oxidation of Arg-410 promotes the elimination of human serum albumin. Biochim. Biophys. Acta. 2006;1764:743-749.

    Not in our library10.1016/j.bbapap.2006.01.011

18. 18.

    Rafferty M.J., McMillan D.C., Preston T.C., Hamid R., Small A.C., Joshi N., Stanley A.J. Reprioritization of liver export protein synthesis in patients with decompensated alcoholic liver disease. J. Hepatol. Gastrointest. Dis. 2016;2.

    Not in our library10.4172/2475-3181.1000135

19. 19.

    Child C.G., Turcotte J.G. Surgery and portal hypertension. Major. Probl. Clin. Surg. 1964;1:1-85.

    Not in our library

20. 20.

    Fulop T., Witkowski J.M., Olivieri F., Larbi A. The integration of inflammaging in age-related diseases. Semin. Immunol. 2018;40:17-35.

    Not in our library10.1016/j.smim.2018.09.003

21. 21.

    Cabrerizo S., Cuadras D., Gomez-Busto F., Artaza-Artabe I., Marín-Ciancas F., Malafarina V. Serum albumin and health in older people: Review and meta analysis. Maturitas. 2015;81:17-27.

    Not in our library10.1016/j.maturitas.2015.02.009

22. 22.

    Lasanianos N., Kanakaris N., Dimitriou R., Pape H., Giannoudis P. Second hit phenomenon: Existing evidence of clinical implications. Injury. 2011;42:617-629.

    Not in our library10.1016/j.injury.2011.02.011

23. 23.

    McMillan D.C., Watson W.S., O’Gorman P., Preston T., Scott H.R., McArdle C.S. Albumin Concentrations Are Primarily Determined by the Body Cell Mass and the Systemic Inflammatory Response in Cancer Patients with Weight Loss. Nutr. Cancer. 2001;39:210-213.

    Not in our library10.1207/s15327914nc392_8

24. 24.

    McSorley S.T., Dolan R.D., Roxburgh C.S.D., McMillan D.C., Horgan P.G. How and why systemic inflammation worsens quality of life in patients with advanced cancer. Expert Rev. Qual. Life Cancer Care. 2017;2:167-175.

    Not in our library10.1080/23809000.2017.1331705

25. 25.

    Ge X., Liu H., Tang S., Wu Y., Pan Y., Liu W., Qi W., Ye L., Cao Q., Zhou W. Preoperative hypoalbuminemia is an independent risk factor for postoperative complications in Crohn’s disease patients with normal BMI: A cohort study. Int. J. Surg. 2020;79:294-299.

    Not in our library10.1016/j.ijsu.2020.05.064

26. 26.

    Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020;383:2255-2273.

    Not in our library10.1056/nejmra2026131

27. 27.

    Schwartzentruber D.J. Guidelines for the Safe Administration of High-Dose Interleukin-2. J. Immunother. 2001;24:287-293.

    Not in our library10.1097/00002371-200107000-00004

28. 28.

    Pockaj B.A., Yang J.C., Lotze M.T., Lange J.R., Spencer W.F., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., White D.E., Rosenberg S.A. A Prospective Randomized Trial Evaluating Colloid Versus Crystalloid Resuscitation in the Treatment of the Vascular Leak Syndrome Associated with Interleukin-2 Therapy. J. Immunother. 1994;15:22-28.

    Not in our library10.1097/00002371-199401000-00003

29. 29.

    Thévenot T., Bureau C., Oberti F., Anty R., Louvet A., Plessier A., Rudler M., Heurgué-Berlot A., Rosa I., Talbodec N., et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J. Hepatol. 2015;62:822-830.

    Not in our library10.1016/j.jhep.2014.11.017

30. 30.

    Naldi M., Baldassarre M., Domenicali M., Bartolini M., Caraceni P. Structural and functional integrity of human serum albumin: Analytical approaches and clinical relevance in patients with liver cirrhosis. J. Pharm. Biomed. Anal. 2017;144:138-153.

    Not in our library10.1016/j.jpba.2017.04.023

31. 31.

    Clerici M., Colombo G., Secundo F., Gagliano N., Colombo R., Portinaro N., Giustarini D., Milzani A., Rossi R., Dalle-Donne I. Cigarette smoke induces alterations in the drug-binding properties of human serum albumin. Blood Cells Mol. Dis. 2014;52:166-174.

    Not in our library10.1016/j.bcmd.2013.12.001

32. 32.

    Era S., Kazuo K., Imai H., Nakamura K., Hayashi T., Sogami M. Age-related change in redox state of human serum albumin. Biochim. Biophys. Acta. 1995;1247:12-16.

    Not in our library10.1016/0167-4838(94)00166-e

33. 33.

    Oettl K., Birner-Gruenberger R., Spindelboeck W., Stueger H.P., Dorn L., Stadlbauer V., Putz-Bankuti C., Krisper P., Graziadei I., Vogel W., et al. Oxidative albumin damage in chronic liver failure: Relation to albumin binding capacity, liver dysfunction and survival. J. Hepatol. 2013;59:978-983.

    Not in our library10.1016/j.jhep.2013.06.013

34. 34.
    Albumin-based drug delivery: harnessing nature to cure disease · 2016

    No notice
35. 35.

    Vlassopoulos A., Lean M., Combet E. Role of oxidative stress in physiological albumin glycation: A neglected interaction. Free. Radic. Biol. Med. 2013;60:318-324.

    Not in our library10.1016/j.freeradbiomed.2013.03.010

36. 36.

    Baldassarre M., Naldi M., Zaccherini G., Bartoletti M., Antognoli A., Laggetta M., Gagliardi M., Tufoni M., Domenicali M., Waterstradt K., et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications. Hepatology. 2021.

    Not in our library10.1002/hep.31798

37. 37.

    Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 2008;8:776-787.

    Not in our library10.1038/nri2402

38. 38.

    Magnussen B., Gradel K.O., Jensen T.G., Kolmos H.J., Pedersen C., Vinholt P.J., Lassen A.T. Association between Hypoalbuminaemia and Mortality in Patients with Community-Acquired Bacteraemia Is Primarily Related to Acute Disorders. PLoS ONE. 2016;11:e0160466.

    Not in our library10.1371/journal.pone.0160466

39. 39.

    Hoth J.J., Smith L.M., Furdui C.M., Wells J.D., Yoza B.K., McCall C.E. Antioxidant treatment after injury suppresses second hit immune priming. J. Trauma Acute Care Surg. 2018;85:367-374.

    Not in our library10.1097/ta.0000000000001951

40. 40.

    Neubert E., Senger-Sander S.N., Manzke V.S., Busse J., Polo E., Scheidmann S.E.F., Schön M.P., Kruss S., Erpenbeck L. Serum and Serum Albumin Inhibit in vitro Formation of Neutrophil Extracellular Traps (NETs). Front. Immunol. 2019;10:12.

    Not in our library10.3389/fimmu.2019.00012

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.